NCT07628738

A Prospective Clinical Study on Reduced-intensity Radiotherapy for Stage I/II Low-risk Nasal-type NK/T-cell Lymphoma Achieving Complete Remission After Chemotherapy

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2026-07-01Est. Completion: 2032-05-01

Enrollment target: 39 participants

Locations

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai Municipality, China

Contact

Shu-Bei Wang, MDwangshubei@163.com +86-021-64370045

Gang Cai, MDcg11855@rjh.com.cn +86-021-64370045

Other microbiome trials you might be interested in

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaPhase 1Recruiting

Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell LymphomaTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

This phase I trial studies the side effects and best dose of mosunetuzumab when given together with polatuzumab vedotin …

Duarte, United StatesEst. completion Jun 30, 2027

View Trial →

KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaPhase 1Recruiting

Non-Hodgkin LymphomaDiffuse Large B Cell Lymphoma (DLBCL)

This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and…

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.